Cannabis, CBD and sleep: what the research says

All sleep articles

By Small Hours · Last reviewed

A hand reaching toward a small unlabelled amber dropper bottle beside a glass of water on a windowsill in soft morning light, a fern at the edge

Sleep is the single most common reason Canadians give for using cannabis medically, and more adults in Canada now use a cannabis product for sleep than use a prescription sleeping pill. [1][2] The best evidence, a Cochrane review published in October 2026, found that medical cannabis may have little or no meaningful effect on sleep quality or total sleep time, with more side effects than placebo, on very uncertain evidence. [6] Other reviews are more positive, and this article shows both. [7][8] What is consistent across the research is that regular use followed by stopping disturbs sleep, which can make cannabis look more helpful than it is. [15][18] If you use cannabis to sleep, this is worth a conversation with your doctor or pharmacist, not a sudden change on your own.

This article is about THC (the part of cannabis that gets you high), CBD (the part that does not), and the few prescription cannabinoid medicines sold in Canada. It gives no amounts, products or schedules. It describes research, and research on this topic is young, small and in places contradictory.

Cannabis in Canada: the short legal picture

The Cannabis Act came into force on 17 October 2018. Adults of legal age in their province can buy cannabis from provincially authorised stores or online platforms, and a separate medical route still exists: a health care provider signs a medical document, and the patient buys from a federally licensed seller or registers to grow a limited amount. [3] In Health Canada's 2024 survey, 10% of people aged 16 and over had used cannabis for medical purposes in the past year, and among them the most common reason given was "problems sleeping or insomnia" (47%), ahead of arthritis (37%) and chronic pain (34%). [1] A separate 2023 survey of 4,037 adults across Canada found that 15.6% had used a cannabis-derived product for sleep in the previous year, slightly more than had used a prescription sleep medication (14.7%), with higher use among men and among adults aged 18 to 35. [2]

Legal does not mean approved as a medicine. Health Canada's own guidance for health professionals states that cannabis is not an approved therapeutic product unless a specific product has been issued a drug identification number, and the Canadian primary-care guideline on medical cannabinoids, which recommends limiting their use in general, names four conditions with some supporting evidence (nerve pain, palliative pain, chemotherapy nausea and vomiting, and spasticity in multiple sclerosis or spinal cord injury). Insomnia is not one of them, and the guideline makes no recommendation about sleep. [4][5]

What the research says

The trials of cannabis for insomnia are few, short and small, and the reviews that pool them disagree. The Cochrane review of October 2026 found nine randomised trials with 537 adults, most of them two weeks long, and concluded that medical cannabis "may have little to no clinically meaningful effect" on sleep quality or total sleep time (about 8 more minutes, with a range from 23 fewer to 38 more), with very-low-certainty evidence and a higher rate of side effects: in the three trials that reported them, 37 people had side effects only during the cannabis period and none only during placebo. [6] A separate 2026 meta-analysis that admitted trials of "poor sleep" as well as insomnia, and allowed melatonin as a comparison, reached a more favourable answer: insomnia severity about 3.7 points lower on a 28-point scale, about 34 more minutes of sleep, and about four times the rate of mostly mild side effects such as dizziness and dry mouth. [7] A 2025 analysis split the trials by ingredient and found that products containing THC improved self-reported sleep quality while CBD-only products showed no significant effect. [8] A 2026 review in JAMA summarised the trial evidence as not supporting cannabis for insomnia. [12] In plain terms, the most conservative and most independent review finds no clear benefit, the broader reviews find a modest one, and all of them say the trials are too short to know what happens with months of nightly use.

The studies behind this
  • Cochrane review (Varela, 2026): nine randomised trials, 537 adults aged 18 to 76, mostly women, mostly with chronic insomnia; eight trials compared cannabis with placebo and one with the antidepressant amitriptyline. Compared with placebo, medical cannabis may have little to no clinically meaningful effect on sleep quality, total sleep time (mean difference 7.68 minutes, 95% CI minus 23.04 to plus 38.39) or daytime functioning, all very-low-certainty evidence. It may slightly increase adverse events (low certainty). The review had no dedicated funding and its authors declared no conflicts. [6]
  • Meta-analysis with broader inclusion (Asim, 2026): ten randomised trials, 2,134 participants with insomnia or sleep disturbance, comparators placebo or melatonin. Cannabinoids reduced insomnia severity (mean difference minus 3.73 on the Insomnia Severity Index), improved sleep quality, increased total sleep time by 33.99 minutes and sleep efficiency by 4.31 percentage points, and shortened time to fall asleep by about 12 minutes. Adverse events were about four times as frequent (relative risk 3.96), mostly mild dizziness and dry mouth. The authors call for larger, longer trials. [7]
  • THC-containing versus CBD-only (da Silva, 2025): six randomised trials, 1,077 people. Cannabinoids improved self-reported sleep quality over placebo overall, but the lower bound of the effect was close to zero and heterogeneity was very high. Products containing cannabinoids other than CBD showed the benefit; CBD-only products showed no significant effect. [8]
  • Earlier meta-analysis (Bhagavan, 2020): found only five studies (two randomised) with 219 participants on cannabinoids for insomnia disorder, rated all of them poor quality, and concluded the evidence could not reliably inform practice. The pooled sleep-quality improvement it reports came from the three non-randomised studies. One ascending-dose study of THC in nine people found faster sleep onset. [11]
  • The two most-cited positive trials: in Western Australia, 24 adults with chronic insomnia took a sublingual cannabinoid extract or placebo for two weeks each. Insomnia severity fell by about 5 points, self-reported sleep rose by about 65 minutes and wrist-measured sleep by 33 minutes, and 36 of the 40 mild side effects occurred on the active product. [9] In Melbourne, 29 adults took a THC-and-CBD oil or placebo for two weeks each; 60% no longer scored as having clinical insomnia at the end of the active period, and a wrist tracker recorded about 21 more minutes of light sleep. The authors note that the effects were larger in the second phase "due to the period effect and loss of blinding". [10]
  • JAMA review (Hsu, 2026): "Evidence from randomized clinical trials does not support the use of cannabis or cannabinoids for most conditions for which it is promoted, such as acute pain and insomnia." It reports that 29% of people using cannabis for medical purposes meet criteria for cannabis use disorder, and advises avoiding use with alcohol or other sedatives, and avoiding driving. [12]

THC: the night you take it, and the nights after

The older research, and Health Canada's summary of it, describe a dose-dependent effect: lower amounts of THC appear to shorten the time to fall asleep and increase deep sleep, while higher amounts appear to disturb sleep, and THC reduces REM sleep, the stage in which most dreaming happens. [4][13] A 2017 review put it as: THC may shorten the time to fall asleep "but could impair sleep quality long-term". [14]

The newer sleep-laboratory evidence is less tidy. A 2025 meta-analysis of studies that measured sleep with brain-wave recording found that cannabis "does not consistently alter" how long people sleep, how fast they fall asleep, how much they wake, or their sleep stages. The classic REM-suppression finding came mainly from small, older studies using high amounts of THC; more recent studies with larger samples and lower amounts have reported mixed and often no REM suppression. [15] The same review names the central puzzle in this field: people report sleeping better on cannabis more often than the laboratory can measure it. [15] In the Australian trial above, the self-reported gain in sleep was about double what the wrist monitor recorded. [9]

What about tolerance? Health Canada's summary documents tolerance to some of THC's effects with repeated use. [4] For sleep specifically, no trial of nightly cannabis has run longer than a few weeks, so whether an early benefit fades is not something the trials can answer; every review asks for longer studies. [6][7][11]

Stopping: withdrawal, and why it matters for insomnia

This is the part of the research that is consistent. Cannabis withdrawal is a recognised diagnosis in both DSM-5 and ICD-10, and it follows stopping long-term regular use. Its symptoms are mainly mood and behavioural, usually light to moderate. [16] Pooling 47 studies of people with regular or dependent use, 47% experienced a withdrawal syndrome on stopping, ranging from 17% in general-population samples to 87% in inpatients, and daily use raised the odds. [17]

Sleep sits at the centre of it. Difficulty sleeping and strange dreams are among the most consistently reported withdrawal symptoms, with a longer time to fall asleep, less deep sleep and a rebound of REM sleep. [13] In a sleep-laboratory study of 20 daily users, three days without cannabis reduced sleep efficiency and total sleep time, lengthened the time to fall asleep, lowered subjective sleep quality and increased REM sleep, compared with nights when they were using; the authors call this clinically significant sleep disruption. [18] The 2025 sleep-architecture review found withdrawal "consistently associated with sleep disturbances" across studies, in contrast to the inconsistent effects of taking it. [15] Brain cannabinoid receptors, which are dampened by regular use, begin to recover within about two days of stopping and return to normal within about four weeks, which the authors of one review suggest as a time frame for withdrawal. [16]

Put those two findings together and a trap appears. If regular use makes sleep worse on the nights you go without, then skipping a night will feel like proof that cannabis works, when what you are feeling is the withdrawal. No single study has followed that loop in people using cannabis for sleep, so it is an implication of the withdrawal research rather than a measured result. It is also the reason that, if nightly cannabis is holding up your sleep, the research supports a planned, gradual change discussed with a clinician rather than an abrupt stop.

CBD on its own

CBD does not cause a high, and hope has run ahead of the evidence. In a sleep-laboratory study of 26 healthy volunteers, a single anxiety-level dose of CBD neither helped nor disturbed sleep compared with placebo. [19] In a two-week pilot trial of 30 adults with moderate-to-severe insomnia, nightly CBD was similar to placebo on insomnia severity, time to fall asleep and time awake at night, although people on CBD reported better well-being and had a small gain in wrist-measured sleep efficiency by the end. [20] The largest CBD-only trial, 125 people with insomnia over four weeks using a THC-free CBD-and-terpene product, found a marginal 1.3 percentage-point rise in time spent in deep-plus-REM sleep on a wrist tracker, no change in total sleep time and no adverse events; it was funded by the product's maker. [21] The meta-analysis that split products by ingredient found no significant effect for CBD-only products. [8]

The study most often quoted in CBD's favour is a chart review, not a trial: 72 psychiatric outpatients took CBD alongside their usual treatment, and sleep scores improved in the first month for two thirds of them but then "fluctuated over time", while anxiety improvements held. There was no placebo group. [22] One more wrinkle: in an early study of eight healthy volunteers, CBD given with THC increased wakefulness during the night and cancelled THC's next-morning drowsiness, which is the origin of the observation that CBD can be alerting rather than sedating. [23]

Cannabinol, or CBN, is marketed as "the sleepy cannabinoid". In the only placebo-controlled sleep-laboratory trial, 20 adults with insomnia disorder took a single dose on one night; it did not change the primary outcome, time awake after falling asleep, though the higher amount shortened sleep onset and improved subjective sleep quality on secondary measures. [24]

Prescription cannabinoid medicines in Canada

Two are sold. Nabilone (Cesamet and generics) is a synthetic THC-like capsule approved for severe nausea and vomiting from chemotherapy. Nabiximols (Sativex) is a mouth spray containing roughly equal THC and CBD. Dronabinol (Marinol) was withdrawn from the Canadian market in 2012 for commercial rather than safety reasons. None is approved for insomnia. [4]

The sleep trials of nabilone are small and in other conditions. In a two-week Canadian crossover trial, 29 people with fibromyalgia and chronic insomnia scored about 3 points better on an insomnia scale with nabilone than with low-dose amitriptyline, with more side effects (dizziness, nausea, dry mouth) and no effect on pain; there was no placebo arm. [25] In a trial of ten Canadian military personnel with post-traumatic stress disorder, nabilone reduced trauma-related nightmares more than placebo, and the authors call for replication and note that its effect on insomnia itself was not studied. [26] For obstructive sleep apnea, the American Academy of Sleep Medicine's position is that medical cannabis and its synthetic extracts should not be used, citing insufficient evidence and unreliable delivery. [27]

Safety: the parts that are well supported

  • Driving. A meta-analysis of 80 studies found THC impairs driving-related skills at peak, that most skills recover within about five hours of inhaling and almost all within seven, and that impairment from swallowed THC may last longer. [28] Health Canada's guidance says combining alcohol with cannabis increases impairment. [4] In the 2024 survey, 16% of past-year users reported driving within two hours of smoking or vaping cannabis. [1]
  • Mixing with sedatives. Health Canada lists drowsiness as additive with other central nervous system depressants, including alcohol and opioids, and names sedative-hypnotics and alcohol among the more clinically significant interactions. [4] The JAMA review advises people using cannabis for a medical condition to avoid combining it with alcohol or other depressants such as benzodiazepines. [12]
  • Interactions with prescription drugs. THC and CBD are broken down by the same liver enzymes as most prescription medicines. A 2024 review of real-world reports found interactions most often with warfarin, valproate, tacrolimus and sirolimus, with bleeding risk and altered mental status among the reported harms. [29] For warfarin specifically, seven published cases link cannabis or CBD with a stronger blood-thinning effect, on very low-quality evidence. [30] If you take any regular medicine, tell your prescriber and pharmacist that you use cannabis.
  • Dependence. Pooling 21 studies, about 22% of people who have used cannabis meet criteria for cannabis use disorder, rising to about a third for dependence among young people using weekly or daily. [31] Among people using it for medical purposes, the JAMA review reports 29%. [12]
  • Side effects reported by users. In the 2024 Canadian survey, the most commonly reported negative effects were anxiety, panic or rapid heartbeat (13%) and drowsiness or lethargy (12%). [1]

Does CBT-I work if you use cannabis?

Almost no one has checked, and we say so. CBT-I is the first-line treatment for chronic insomnia in practice guidelines, as the Canadian survey authors note. [2] Whether it works as well for people who also use cannabis nightly is being tested: a 200-person randomised trial of CBT-I for adults with both chronic insomnia and frequent cannabis use published its protocol in 2026, with no results yet. [32] Until then, the honest position is that CBT-I treats the insomnia, and that a person who is tapering a nightly cannabis habit will, on the withdrawal research above, have some rough nights in the middle of doing so. [15][18]

For clinicians

The 2026 Cochrane review is the most conservative and most independent synthesis and finds no clinically meaningful benefit on very-low-certainty evidence; the 2026 and 2025 meta-analyses with broader inclusion find a modest subjective benefit driven by THC-containing products. [6][7][8] The Canadian primary-care guideline makes no recommendation on insomnia. [5] The withdrawal literature (DSM-5 syndrome, 47% pooled prevalence among regular users, polysomnographic disruption within three days of abstinence) is the part most relevant to a patient who reports that cannabis "is the only thing that works". [16][17][18] The JAMA review's harm-reduction points, no co-use with alcohol or benzodiazepines, no driving, and screening for use disorder, apply. [12] Small Hours has a page for clinicians whose patients use the program.

Where the evidence is thin

  • The trials are two to four weeks long. Nobody has tested nightly cannabis for sleep over months. [6][7][11]
  • The pooled reviews disagree because they include different trials; the disagreement is real and unresolved. [6][7][8]
  • Self-reported sleep improves more than laboratory-measured sleep does, and the field has not explained why. [9][15]
  • Several positive trials were small, lost their blinding, or were funded by product makers. [10][21]
  • The classic THC-suppresses-REM finding rests on older, high-amount studies and is inconsistent at lower amounts. [15]
  • We found no study that directly measured the withdrawal loop in people who use cannabis specifically for sleep. [15][18]
  • Nothing here is specific to British Columbia, and Health Canada notes its survey may give higher use estimates than other Canadian surveys. [1]

Where does this leave you?

If cannabis is part of your nights and your sleep is still poor, the research gives you two useful facts: the benefit in trials is small or uncertain, and stopping abruptly after regular use reliably makes sleep worse for a while. Both point to the same move, which is a conversation with your doctor or pharmacist rather than a change on your own. Small Hours is a six-week CBT-I program built from your own sleep diary. It does not give advice about cannabis or any other substance, and it works alongside the care you already have. You can sign up at trysmallhours.com.

When should you talk to a doctor?

  • Before stopping or reducing regular cannabis use, so that the change is planned and the rough nights are expected rather than alarming.
  • If you take warfarin, anti-seizure medicines, transplant medicines or any other regular prescription, before using cannabis or CBD. [29][30]
  • If you use cannabis most days and find it hard to cut down, or it is causing anxiety or panic. [1][31]
  • Sleep trouble lasting months, loud snoring or breathing pauses, or low mood that comes with the poor sleep. If you are in distress in Canada, call or text 9-8-8 at any hour.

General education, not medical advice.

References

  1. Health Canada. Canadian Cannabis Survey 2024: Summary. Ottawa: Health Canada; page updated 6 March 2026. Source for reference 1 (opens in a new tab)
  2. Morin CM, Vézina-Im LA, Chen SJ, et al. Prevalence of insomnia and use of sleep aids among adults in Canada. Sleep Med. 2024;124:338-345. Source for reference 2 (opens in a new tab)
  3. Health Canada. Cannabis for medical purposes under the Cannabis Act: information and improvements. Ottawa: Health Canada; page updated 23 May 2024. Source for reference 3 (opens in a new tab)
  4. Health Canada. Information for Health Care Professionals: Cannabis (marihuana, marijuana) and the cannabinoids. Ottawa: Health Canada; Spring 2018 (latest version). Source for reference 4 (opens in a new tab)
  5. Allan GM, Ramji J, Perry D, et al. Simplified guideline for prescribing medical cannabinoids in primary care. Can Fam Physician. 2018;64(2):111-120. Source for reference 5 (opens in a new tab)
  6. Varela LB, Miño Zambrano JE, Maura Goncalves Costa B, et al. Medical cannabis for the treatment of insomnia. Cochrane Database Syst Rev. 2026;10(10):CD016216. Source for reference 6 (opens in a new tab)
  7. Asim R, Azeem B, Wijdan SA, et al. Efficacy of cannabinoids for insomnia and sleep disturbance: a systematic review and meta-analysis of randomized controlled trials. Sleep Med. 2026;148:109193. Source for reference 7 (opens in a new tab)
  8. da Silva GHS, Barbosa EC, de Lima FR, et al. Effectiveness of cannabinoids on subjective sleep quality in people with and without insomnia or poor sleep: a systematic review and meta-analysis of randomised studies. Sleep Med Rev. 2025;84:102156. Source for reference 8 (opens in a new tab)
  9. Walsh JH, Maddison KJ, Rankin T, et al. Treating insomnia symptoms with medicinal cannabis: a randomized, crossover trial of the efficacy of a cannabinoid medicine compared with placebo. Sleep. 2021;44(11):zsab149. Source for reference 9 (opens in a new tab)
  10. Ried K, Tamanna T, Matthews S, Sali A. Medicinal cannabis improves sleep in adults with insomnia: a randomised double-blind placebo-controlled crossover study. J Sleep Res. 2023;32(3):e13793. Source for reference 10 (opens in a new tab)
  11. Bhagavan C, Kung S, Doppen M, et al. Cannabinoids in the treatment of insomnia disorder: a systematic review and meta-analysis. CNS Drugs. 2020;34(12):1217-1228. Source for reference 11 (opens in a new tab)
  12. Hsu M, Shah A, Jordan A, Gold MS, Hill KP. Therapeutic use of cannabis and cannabinoids: a review. JAMA. 2026;335(4):345-359. Source for reference 12 (opens in a new tab)
  13. Schierenbeck T, Riemann D, Berger M, Hornyak M. Effect of illicit recreational drugs upon sleep: cocaine, ecstasy and marijuana. Sleep Med Rev. 2008;12(5):381-389. Source for reference 13 (opens in a new tab)
  14. Babson KA, Sottile J, Morabito D. Cannabis, cannabinoids, and sleep: a review of the literature. Curr Psychiatry Rep. 2017;19(4):23. Source for reference 14 (opens in a new tab)
  15. Velzeboer R, Malas A, Wei S, et al. Cannabis and sleep architecture: a systematic review and meta-analysis. Sleep Med Rev. 2025;84:102164. Source for reference 15 (opens in a new tab)
  16. Bonnet U, Preuss UW. The cannabis withdrawal syndrome: current insights. Subst Abuse Rehabil. 2017;8:9-37. Source for reference 16 (opens in a new tab)
  17. Bahji A, Stephenson C, Tyo R, et al. Prevalence of cannabis withdrawal symptoms among people with regular or dependent use of cannabinoids: a systematic review and meta-analysis. JAMA Netw Open. 2020;3(4):e202370. Source for reference 17 (opens in a new tab)
  18. Vandrey R, Smith MT, McCann UD, Budney AJ, Curran EM. Sleep disturbance and the effects of extended-release zolpidem during cannabis withdrawal. Drug Alcohol Depend. 2011;117(1):38-44. Source for reference 18 (opens in a new tab)
  19. Linares IMP, Guimaraes FS, Eckeli A, et al. No acute effects of cannabidiol on the sleep-wake cycle of healthy subjects: a randomized, double-blind, placebo-controlled, crossover study. Front Pharmacol. 2018;9:315. Source for reference 19 (opens in a new tab)
  20. Narayan AJ, Downey LA, Rose S, Di Natale L, Hayley AC. Cannabidiol for moderate-severe insomnia: a randomized controlled pilot trial of 150 mg of nightly dosing. J Clin Sleep Med. 2024;20(5):753-763. Source for reference 20 (opens in a new tab)
  21. Wang M, Faust M, Abbott S, et al. Effects of a cannabidiol/terpene formulation on sleep in individuals with insomnia: a double-blind, placebo-controlled, randomized, crossover study. J Clin Sleep Med. 2025;21(1):69-80. Source for reference 21 (opens in a new tab)
  22. Shannon S, Lewis N, Lee H, Hughes S. Cannabidiol in anxiety and sleep: a large case series. Perm J. 2019;23:18-041. Source for reference 22 (opens in a new tab)
  23. Nicholson AN, Turner C, Stone BM, Robson PJ. Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. J Clin Psychopharmacol. 2004;24(3):305-313. Source for reference 23 (opens in a new tab)
  24. Lavender IG, Marshall NS, McCartney D, et al. Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial. J Sleep Res. 2026;35(4):e70284. Source for reference 24 (opens in a new tab)
  25. Ware MA, Fitzcharles MA, Joseph L, Shir Y. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg. 2010;110(2):604-610. Source for reference 25 (opens in a new tab)
  26. Jetly R, Heber A, Fraser G, Boisvert D. The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: a preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology. 2015;51:585-588. Source for reference 26 (opens in a new tab)
  27. Ramar K, Rosen IM, Kirsch DB, et al. Medical cannabis and the treatment of obstructive sleep apnea: an American Academy of Sleep Medicine position statement. J Clin Sleep Med. 2018;14(4):679-681. Source for reference 27 (opens in a new tab)
  28. McCartney D, Arkell TR, Irwin C, McGregor IS. Determining the magnitude and duration of acute Δ9-tetrahydrocannabinol (Δ9-THC)-induced driving and cognitive impairment: a systematic and meta-analytic review. Neurosci Biobehav Rev. 2021;126:175-193. Source for reference 28 (opens in a new tab)
  29. Nachnani R, Knehans A, Neighbors JD, et al. Systematic review of drug-drug interactions of delta-9-tetrahydrocannabinol, cannabidiol, and Cannabis. Front Pharmacol. 2024;15:1282831. Source for reference 29 (opens in a new tab)
  30. Smythe MA, Wu W, Garwood CL. Anticoagulant drug-drug interactions with cannabinoids: a systematic review. Pharmacotherapy. 2023;43(12):1327-1338. Source for reference 30 (opens in a new tab)
  31. Leung J, Chan GCK, Hides L, Hall WD. What is the prevalence and risk of cannabis use disorders among people who use cannabis? A systematic review and meta-analysis. Addict Behav. 2020;109:106479. Source for reference 31 (opens in a new tab)
  32. Bolling C, Cardoni ME, Conroy DA, et al. Cognitive-behavioural therapy for insomnia in adults to decrease cannabis use: study protocol for a randomised controlled trial in a community sample of adults with frequent cannabis use. BMJ Open. 2026;16(6):e116524. Source for reference 32 (opens in a new tab)

This article is general education, not medical advice. It cannot diagnose anything or replace a conversation with your doctor. Read how we choose and check sources on the how we write page.

Share this article

Know someone who is lying awake? Send it to them.

Make the small hours smaller

Small Hours is a free sleep diary with a six-week CBT-I program behind it, built on the same research. Sign up tonight, and fill in your first two-minute diary tomorrow morning.

Create an account

Small Hours is a self-guided program for adults. It is not an emergency service. If you are in crisis, call or text 9-8-8 in Canada or the US at any hour.